Skip to main content
SpringerLink
Log in

Nierinsufficiëntie en medicatie

  • Artikelen
  • Published:
Bijblijven

Samenvatting

In de huisartsenpraktijk neemt het aantal patiënten met een verminderde nierfunctie toe. Veel geneesmiddelen worden renaal uitgescheiden, wat onder andere consequenties heeft voor de dosering van deze geneesmiddelen. Het is in de dagelijkse praktijk niet altijd gemakkelijk hiermee om te gaan. In deze bijdrage gaan we dieper in op de beoordeling van de nierfunctie en geven we vervolgens achtergrondinformatie en praktische adviezen omtrent het gebruik van antibiotica, orale antidiabetica, ACE-remmers, NSAID’s, diuretica en de nieuwe directe orale anticoagulantia (DOAC) bij nierinsufficiëntie.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatuur

  1. Harm-rapport (Hospital Admissions Related to Medication). Utrecht: Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology & Pharmacotherapy, November 2006.

  2. Leendertse AJ, Dijk EA van, Smet PA de, Egberts TC, Bemt PM van den. Contribution of renal impairment to potentially preventable medication-related hospital admissions. Ann Pharmacother 2012 May;46(5):625–33.

    Article  PubMed  Google Scholar 

  3. Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005;16:763–73.

    Article  PubMed  Google Scholar 

  4. Verhave JC, Kramers C, Wetzels JFM. Nieuwe formule leidt tot betere schattingen. Pharm Weekbl 2007;142(40):18–21.

    Google Scholar 

  5. Felts JH, Hayes DM, Gergen JA, Toole JF. Neural, hematologic and bacteriologic effects of nitrofurantoin in renal insufficiency. Am J Med 1971;51:331–9.

    Article  CAS  PubMed  Google Scholar 

  6. Thieler H, Meyer W. Nil nocere! Severe polyneuropathy during nitrofurantoin therapy of renal insufficiency. Dtsch Gesundheitsw 1968;23:488–91.

    CAS  PubMed  Google Scholar 

  7. Geerts AF, et al. Ineffectiveness and adverse events of nitrofurantoin in women with urinary tract infection and renal impairment in primary care. Eur J Clin Pharmacol 2013 Sep;69(9):1701–7.

    Article  CAS  PubMed  Google Scholar 

  8. Siber GR, Gorham CC, Ericson JF, Smith AL. Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole in children and adults with normal and impaired renal function. Rev Infect Dis 1982 Mar-Apr;4(2):566–78.

    Article  CAS  PubMed  Google Scholar 

  9. Rigalleau V, et al. Estimation of renal function in patients with diabetes. Diabetes Metab 2011;37(5):359–66.

    Article  CAS  PubMed  Google Scholar 

  10. Linden CMJ van der, Knol W, Marum RJ van, Jansen PA. Lactaatacidose bij een 85-jarige vrouw door behandeling met metformine. Ned Tijdschr Geneeskd 2007;151:977–80.

    PubMed  Google Scholar 

  11. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999:489–503.

  12. Graham GG, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011;50 (2):81–98.

    Article  CAS  PubMed  Google Scholar 

  13. Jönsson A, Rydberg T, Sterner G, Melander A. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol 1998;53:429–35.

    Article  PubMed  Google Scholar 

  14. Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 1996;39:1617–24.

    Article  CAS  PubMed  Google Scholar 

  15. Marbury TC, et al. Pharmacokinetics of repaglinide in subjects with renal impairment.Clin Pharmacol Ther 2000 Jan;67(1):7–15.

    Article  CAS  PubMed  Google Scholar 

  16. Lam FYW, Banerji S, Hatfield C, Talbert RL. Principles of drug administration in renal insufficiency. Clin Pharmocokinet 1997 Jan;32 (1):30–57.

    Article  CAS  Google Scholar 

  17. Boulton D, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 2011 Apr;50(4):253–65.

    Article  CAS  PubMed  Google Scholar 

  18. Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 2011;13:947–54.

    Article  CAS  PubMed  Google Scholar 

  19. Bergman AJ, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007;30:1862–4.

    Article  CAS  PubMed  Google Scholar 

  20. Linneberg H, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007;64:317–27.

    Article  Google Scholar 

  21. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009 Dec;68(6):898–905.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Bootsma JE, et al. Adherence to biochemical monitoring recommendations in patients starting with renin angiotensin system inhibitors: a retrospective cohort study in the Netherlands. Drug Saf 2011 Jul 1;34(7):605–14.

    Article  PubMed  Google Scholar 

  23. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999 May 31;106(5B):13S-24S.

    Article  CAS  PubMed  Google Scholar 

  24. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal anti-inflammatory drugs. New Engl J Med 1984;310:563–72.

    Article  CAS  PubMed  Google Scholar 

  25. Niemeyer C, Hasenfuss G, Wais U, Knauf H, Schäfer-Korting M, Mutschler E. Pharmacokinetics of hydrochloorthiazide in relation to renal function. Eur J Clin Pharmacol 1983;24:661–5.

    Article  CAS  PubMed  Google Scholar 

  26. Traeger A, et al. Pharmacokinetic and pharmacodynamic effects of furosemide in patients with impaired renal function. Int J Clin Pharmacol Ther Toxicol 1984;22(9):481–6.

    CAS  PubMed  Google Scholar 

  27. Syropoulus AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 2012;120(15):2954–62.

    Article  Google Scholar 

  28. Steffel J, Hindrick G. Apixaban in renal insufficiency: successful navigation between the Scylla and Charybdis. Eur Heart J 2012;33:2766–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. klinisch farmacoloog, Radboudumc, Nijmegen, The Netherlands

    Anne Esselink

  2. Eerstelijnsvervolgopleidingen, Radboudumc, Nijmegen, The Netherlands

    Nynke (D.) Scherpbier-de Haan

  3. klinisch farmacoloog, Canisius-Wilhelmina ziekenhuis en Radboudumc, Nijmegen, The Netherlands

    Kees Kramers

Authors
  1. Nynke (D.) Scherpbier-de Haan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kees Kramers
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

internist in opleiding – klinisch farmacoloog in opleiding, Radboudumc, Nijmegen

huisarts en hoofd Eerstelijnsvervolgopleidingen, Radboudumc Nijmegen

internist-klinisch farmacoloog, Canisius-Wilhelmina ziekenhuis en Radboudumc, Nijmegen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Esselink, A., Scherpbier-de Haan, N. & Kramers, K. Nierinsufficiëntie en medicatie. Bijblijven 30, 54–60 (2014). https://doi.org/10.1007/s12414-014-0024-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12414-014-0024-7

Search

Navigation